.Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CD05_Triazolam.Triazolam

Information

Triazolam is a short-acting benzodiazepine used primarily for the treatment of insomnia. It is indicated for short-term management of sleep disorders and is not recommended for long-term use due to dependence and tolerance risks. Triazolam is still available in some countries but its use is restricted or discontinued in others due to safety concerns.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers (male and female), age 19-38 years, after a single oral dose.

References

1. Friedman, H, et al., & Shader, RI (1986). Population study of triazolam pharmacokinetics. British journal of clinical pharmacology 22(6) 639–642. DOI:10.1111/j.1365-2125.1986.tb02951.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/3567010

2. Ozdemir, V, et al., & Naranjo, CA (1996). Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?. Clinical pharmacokinetics 31(5) 372–385. DOI:10.2165/00003088-199631050-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9118585

3. Perucca, E, et al., & Fuseau, E (2008). Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 49(7) 1123–1141. DOI:10.1111/j.1528-1167.2008.01665.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/18503564

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)